For questions regarding claiming CME Credit, please refer to our FAQ section.


 
 

 

 

Post ACC 14: Focus on TAVR

    

Program Overview:

Over 50,000 TAVR procedures have been performed globally.1 With the development of multiple systems for TAVR, best practice questions have formed. Late-breaking trials from ACC offered an examination of key topics including comparison of TAVR devices and post-marketing safety in the United States to further refine the use of this technology and insights into device and patient selection. Results discussed include:

  • CoreValve in high-risk surgical patients vs surgical aortic valve replacement
  • CHOICE trial comparing the two available TAVR systems—balloon expandable (Sapien) and self-expanding (CoreValve)
  • One-year outcomes from the STS/ACC Transcatheter Valve Therapy Registry

Click Here to access this CME Program

 

Release Date:
June 16th, 2014

 

Expiration Date:
December 16th, 2014 

  Estimated Time:
1 hour

 

 

 

ACC 14: Focus on Renal Denervation

                                                      

Program Overview:

One-in-ten hypertension cases is treatment resistant (ie, inadequate response with 3 or more antihypertensives). While renal denervation has proven safe for treating severe hypertension, the latest results from SYMPLICITY HTN-3 render its efficacy unclear. Patient selection remains one of the biggest challenges, as 20% of patients are non-responders in clinical trials. At ACC 2014, SYMPLICITY HTN-3 primary results and the Global SYMPLICITY registry, which looks at post-approval real-world outcomes on multiple continents, were presented. This webcast will review key results. A panel discussion will provide context for the SYMPLICITY HTN-3 and GLOBAL SYMPLICITY results and implications for the field of renal denervation.

Click Here to access this CME Program

 

Release Date:
June 16th, 2014

 

Expiration Date:
December 16th, 2014 

  Estimated Time:
1 hour

 

 

 

Future of Valve Surgery CME Webcast

Program Overview:

This program is geared toward the surgeon seeking to gain confidence in performing minimally invasive valve procedures. Participants will discuss the clinical and practical aspects involved in establishing a successful structural heart and valve program. In addition, sessions will examine new technological developments in the field, such as stented and sutureless valves, as well as future directions in valvular repair and replacement.

Click Here to access this CME Program

 

Release Date:
May 28th, 2014

 

Expiration Date:
November 28, 2014 

  Estimated Time:
45 Minutes

 

 

Enhancing ACS Outcomes

 

Program Overview:

Antiplatelet therapy is a complex and integral part of care for patients who present with ACS or undergo percutaneous coronary intervention (PCI) and individualization of antiplatelet therapy is essential to delivering guideline-directed care. Selecting antiplatelet therapy continues to be one of the single greatest challenges in interventional cardiology practice, and is the topic of intense debate in current literature. Although truly individualized management is not yet possible, many inferences can be made based on the existing body of evidence. In order to provide evidence-based care for patients and minimize the risk of ischemic complications, interventional cardiologists must inspect many different perspectives regarding what factors to consider in antiplatelet selection. This activity will provide interventionalists with the necessary framework for tailoring antiplatelet therapy in patients at risk for acute coronary syndromes.

Click Here to access this CME Program

 

Release Date:
January 31, 2014

 

Expiration Date:
July 31, 2014 

  Estimated Time:
1 hour